Read this first
This is plain-language harm-reduction information, not medical advice. Peptides discussed here are research compounds; most are not approved for human use. People will use them either way — we would rather they have the facts.
What it is
Tesamorelin is a synthetic GHRH analogue similar to sermorelin but stabilised to last longer in the bloodstream.
Unlike most peptides discussed here, tesamorelin has a real human approval — it is FDA-approved as Egrifta for the treatment of excess abdominal fat in HIV-associated lipodystrophy. The visceral-fat angle is what makes it popular outside that approval.
History
Developed by Theratechnologies. FDA-approved (Egrifta) in 2010 for HIV-associated lipodystrophy.
How it works
Binds the GHRH receptor and stimulates GH release. Stabilised against rapid enzymatic breakdown.
Dosage
- Clinical dose: 2 mg once daily.
- Body recomposition users: 1–2 mg once daily, usually before bed.
How it is taken
- Subcutaneous belly injection.
How to reconstitute
- A 5 mg vial with 2 ml BAC water = 2.5 mg/ml. 1 mg = 40 units on a 1 ml insulin syringe.
How it should arrive
White powder, sealed vial.
How it should look once reconstituted
Clear colourless solution.
What to expect, and when
- Visceral fat reduction: 8–12 weeks at clinical dose.
- Other GH benefits (sleep, recovery): similar window to other GHRH analogues.
Side effects
- Injection-site reactions.
- Joint discomfort.
- Mild fluid retention.
- Vivid dreams.
Risks
- Possible mild blood-sugar effects.
- Theoretical GH/IGF-1 concern long-term.
- WADA prohibited.
Potential gains
- Documented visceral fat reduction in clinical trials.
- Standard GH-related benefits (sleep, recovery, skin).
Other useful information
The peptide to consider if visceral (belly) fat specifically is your goal. Pricier than other GHRH analogues.
Looking for a goal-based recommendation?
Try the Find your goal tool — answer five short questions and get peptides matched to what you actually want.